Status:
COMPLETED
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
Lead Sponsor:
SK Life Science, Inc.
Conditions:
Refractory Epilepsy
Eligibility:
All Genders
18-79 years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are betw...
Eligibility Criteria
Inclusion
- Age 18-70 years old,
- Diagnosis of epilepsy for at least 1 year,
- Presenting, on average, at least 3 partial onset seizures per month,
- Currently treated with a stable dose (i.e., for at least 4 weeks) of no more than 3 anti-epileptic drugs (AEDs),
Exclusion
- Have experienced status epilepticus in the past 3 months,
- Have any serious diseases,
- History of major psychiatric disorders within the past 2 years.
- Have received an experimental drug/device within the past 30 days
- Are pregnant or breastfeeding.
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00228969
Start Date
February 1 2005
End Date
May 1 2006
Last Update
August 2 2012
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Huntsville, Alabama, United States
3
Mobile, Alabama, United States
4
Northport, Alabama, United States